NTU researchers identify lung cancer-related mutation
A research team from National Taiwan University (NTU) has succeeded in identifying a genome mutation highly correlated with lung cancer using rapid whole-genome sequencing technology, and the discovery can improve the diagnosis of early stage lung cancer.
At a press briefing Thursday, researchers said that lung cancer remained the No. 1 killer among all diseases in Taiwan. Most lung cancers are first diagnosed based on symptoms, but symptoms of early-stage lung cancer are not very specific, thus causing difficulties in screening.
At the moment, the only method to identify groups with a high risk of developing lung cancer is resorting to familial penetrance.
In order to identify the risk factors, the research team conducted a study of a family with an atypically high density of lung cancer. By analyzing the data collected in the process of conducting rapid wholegenome sequencing of family members, the researchers succeeded in identifying a key genome mutation.
In addition, the researchers also conducted validation studies among more than 1,000 persons, some of whom were lung cancer patients. The researchers found that the lung cancer risk in YAP1 (yes-associated protein 1) mutantallele carriers was 5.9 times that of non-carriers.
National Taiwan University President Dr. Pan-chyr Yang, center, and his team of researchers announce their successful identification of a genome mutation that could help research in lung cancer, yesterday. The research showed positive results by using rapid whole-genome sequencing technology to discover a gene mutation that is linked to lung cancer; thus, further aiding diagnoses of lung cancer in its early stages.